
Novo Nordisk, Denmark's biggest pharmaceutical company, has established a new unit with the ambition of making RNA and gene therapy available across all of its therapy areas, Senior Vice President of Global Research Technologies at Novo Nordisk tells Medwatch.
"One of the main reasons we are taking this leap is our belief that RNA and gene therapy could be used within all of Novo Nordisk's therapy areas," Fogh Iversen says.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.